Nivolumab+bevacizumab shows benefit in relapsed ovarian cancer

  • Liu JF & al.
  • JAMA Oncol
  • 10 Oct 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Nivolumab+bevacizumab is safe and tolerable in patients with relapsed ovarian cancer.
  • Women with platinum-sensitive disease demonstrated a higher objective response rate (ORR).

Why this matters

  • Single-agent PD-1/PD-L1 therapy has limited activity in ovarian cancer.
  • Alternative immunotherapy combinations should be explored in the platinum-resistant setting.

Study design

  • Phase 2 study of 38 women with relapsed epithelial ovarian cancer who experienced recurrence within 12 months of their last platinum-based therapy received nivolumab+intravenous bevacizumab.
  • PD-L1 testing (n=36):
  • Funding: Bristol-Myers Squibb.

Key results

  • 18 patients had platinum-resistant and 20 had platinum-sensitive disease.
  • Confirmed response was reported in 11 patients (ORR, 28.9%; 95% CI, 15.4%-45.9%); 1 additional patient had an unconfirmed response.
    • 10 responses occurred in 
  • ORR was 40.0% in platinum-sensitive and 16.7% in platinum-resistant patients.
  • Median PFS was 8.1 (95% CI, 6.3-14.7) months.
  • Median duration of response was longer in platinum-resistant disease (12.3 vs 5.6 months), but PFS was shorter (5.3 vs 9.4 months).
  • Overall clinical benefit rate (response+stable disease >24 weeks) was 55.3%.
  • 89.5% of patients reported ≥1 treatment-related adverse event (grade ≥3, 23.7%).

Limitations

  • Single group.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit